Pirfenidone for treating idiopathic pulmonary fibrosis

Equality Impact Assessment (Guidance development) (PDF 258 KB)

Roche Products Limited : Appeal letter (PDF 652 KB)

Roche Products Limited : Scrutiny letter (PDF 96 KB)

British Thoracic Society : Appeal letter (PDF 174 KB)

British Thoracic Society : Scrutiny letter (PDF 91 KB)

Appeal decision : Appeal letter (PDF 439 KB)

Final appraisal determination: 2

Final appraisal determination document (PDF 159 KB)

Committee papers (PDF 913 KB)

Public committee slides (PDF 289 KB)

Appeal

Roche Products Ltd : Appeal letter (PDF 707 KB)

NICE : Scrutiny letter (PDF 204 KB)

Roche Products Ltd : Response to scrutiny letter (PDF 274 KB)

NICE : Final scrutiny letter (PDF 275 KB)

Appeal decision : Appeal letter (PDF 308 KB)

Final appraisal determination

Final appraisal determination document (PDF 333 KB)

Committee papers (PDF 1.78 MB)

Committee papers (PDF 969 KB)

Draft guidance: 1

Appraisal consultation document (PDF 166 KB)

Committee papers (PDF 9.3 MB)

Draft scope and provisional matrix comments table (post-referral) (PDF 218 KB)

Final matrix (PDF 91 KB)

Final scope (PDF 83 KB)

Idiopathic pulmonary fibrosis - pirfenidone (review TA282): draft scope for consultation (post-referral) (PDF 47 KB)

Idiopathic pulmonary fibrosis - pirfenidone (review TA282): provisional matrix (post-referral) (PDF 30 KB)